Biogen

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Biogen and other ETFs, options, and stocks.

About BIIB

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.

CEO

Christopher A. Viehbacher

CEOChristopher A. Viehbacher

Employees

7,500

Employees7,500

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

1978

Founded1978

Employees

7,500

Employees7,500

BIIB Key Statistics

Market cap

35.61B

Market cap35.61B

Price-Earnings ratio

43.05

Price-Earnings ratio43.05

Dividend yield

—

Dividend yield—

Average volume

1.34M

Average volume1.34M

High today

$247.03

High today$247.03

Low today

$240.15

Low today$240.15

Open price

$242.02

Open price$242.02

Volume

804.49K

Volume804.49K

52 Week high

$247.03

52 Week high$247.03

52 Week low

$138.00

52 Week low$138.00

Stock Snapshot

As of today, Biogen(BIIB) shares are valued at $240.98. The company's market cap stands at 35.61B, with a P/E ratio of 43.05.

On 2026-10-21, Biogen(BIIB) stock traded between a low of $240.15 and a high of $247.03. Shares are currently priced at $240.98, which is +0.3% above the low and -2.4% below the high.

Biogen(BIIB) shares are trading with a volume of 804.49K, against a daily average of 1.34M.

During the past year, Biogen(BIIB) stock moved between $138.00 at its lowest and $247.03 at its peak.

BIIB News

TipRanks 10h

Biogen price target raised to $250 from $225 at TD Cowen

TD Cowen raised the firm’s price target on Biogen (BIIB) to $250 from $225 and keeps a Buy rating on the shares. The firm updated its model ahead of Q3 results...

TipRanks 2d

Biogen’s BIIB147 ALS Trial: A Long-Horizon Catalyst for Neurology Investors

Biogen Inc. (BIIB) announced an update on their ongoing clinical study. Biogen Inc. (BIIB) is running a new first-in-human study of BIIB147 for amyotrophic lat...

Simply Wall St 5d

Biogen On Lupus Trial Results Looks Fully Valued Or Still Worth Buying

Biogen (BIIB) shares are in focus after the company released 52-week Phase 2 results from its AMETHYST trial of litifilimab in cutaneous lupus erythematosus, hi...

Analyst ratings

68%

of 37 ratings

Buy

67.6%

Hold

29.7%

Sell

2.7%

People also own

Based on the portfolios of people who own BIIB. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.